Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Name: Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
Published: 2020
License: Public Domain

Basilea Pharmaceutica · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

gastric-cancer paclitaxel targeted-therapy

gastric adenocarcinoma, gastric cancer, gastro-esophageal adenocarcinoma, adenocarcinoma of the stomach or gastro-esophageal junction, fibroblast growth factor receptor, fgfr genetic aberration, targeted therapy, derazantinib, atezolizumab, tecentriq, paclitaxel, ramucirumab

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 871703
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.